TSE:4578Pharmaceuticals
The Bull Case For Otsuka Holdings (TSE:4578) Could Change Following Upgraded 2026 Earnings Guidance - Learn Why
In July 2026, Otsuka Holdings Co., Ltd. raised its consolidated earnings guidance for the first half of 2026, now projecting revenue of ¥1,332,000 million and operating profit of ¥278,000 million, with basic earnings per share guided to ¥407.90.
The upgrade reflects stronger-than-expected demand for key drugs such as JYNARQUE, ABILIFY MAINTENA, VOYXACT, REXULTI, and LONSURF, a weaker yen boosting overseas revenues, and lower projected research and development spending after discontinuing...